Sciwind Biosciences
PrivateLast Round
IPO
Mar 23, 2026
Est. Valuation
$676M
Total Funding Raised
$336.48M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Sciwind Biosciences operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a Series D round in December 2024.
Sciwind Biosciences is a biopharmaceutical company that develops innovative therapies for the treatment of metabolic diseases, including obesity and type 2 diabetes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Sciwind Biosciences Comparables
Compare Sciwind Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QL Biopharm | 87% | |
| Verdiva Bio | 84% | |
| Kailera Therapeutics | 83% |
For institutional investors. Book with your work email.
Sciwind Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 23, 2026 | ||||
| Growth Equity | Jan 10, 2025 | ||||
| Series D | Dec 1, 2024 | ||||
| Series C Extension | Mar 1, 2023 | ||||
| Series C Extension | Dec 1, 2021 | ||||
Series C | Oct 12, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Sciwind Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loyal Valley Capital | Series C |
| IDG Capital | Series C |
| Oriza Holdings | Series B |
| Kaitai Capital | Series B |
| China International Capital Corporation | IPO |
| LYFE Capital | Series C, Series B |
| Legend Capital | Series C, Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors increased 169% MoM.
- Jun 12, 2026
8 trial approvals obtained, 2 products advanced to Phase III.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologyNov 3, 2026
Hangzhou Sciwind Biosciences Co., Ltd. licenses Pfizer Inc mainland China rights to Ecnoglutide, a GLP-1 receptor agonist injection, for $495 million in upfront and potential milestone payments; the drug is approved in China for type 2 diabetes, and a weight-loss marketing application is accepted there.
For institutional investors. Book with your work email.
Sciwind Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Sciwind Biosciences's valuation, stock price, and market status.
Is Sciwind Biosciences a public or private company?
Sciwind Biosciences is a private company.
What is the current stock price of Sciwind Biosciences?
Sciwind Biosciences is a private company, so its shares have no public market price. Caplight tracks Sciwind Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Sciwind Biosciences worth (valuation)?
Sciwind Biosciences's valuation is estimated at $676.0M based on funding round data.
Can I buy Sciwind Biosciences stock?
Sciwind Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Sciwind Biosciences's last funding round?
Sciwind Biosciences's most recent funding round was IPO on March 23, 2026.
Who are the main investors in Sciwind Biosciences?
Key investors in Sciwind Biosciences include Loyal Valley Capital, IDG Capital, China International Capital Corporation, LYFE Capital, Legend Capital.
Will Sciwind Biosciences IPO soon?
No public IPO plans have been announced for Sciwind Biosciences.
How can I track Sciwind Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Sciwind Biosciences's shares on secondary markets.